CN107184863A - 食材提取物和营养素广谱抗肿瘤组合物及其制备方法 - Google Patents
食材提取物和营养素广谱抗肿瘤组合物及其制备方法 Download PDFInfo
- Publication number
- CN107184863A CN107184863A CN201710346878.4A CN201710346878A CN107184863A CN 107184863 A CN107184863 A CN 107184863A CN 201710346878 A CN201710346878 A CN 201710346878A CN 107184863 A CN107184863 A CN 107184863A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- food materials
- nutrient
- broad
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 145
- 239000000463 material Substances 0.000 title claims abstract description 40
- 235000013305 food Nutrition 0.000 title claims abstract description 39
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000002994 raw material Substances 0.000 claims abstract description 26
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000004472 Lysine Substances 0.000 claims abstract description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 14
- ZIALXKMBHWELGF-UHFFFAOYSA-N [Na].[Cu] Chemical compound [Na].[Cu] ZIALXKMBHWELGF-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960003080 taurine Drugs 0.000 claims abstract description 13
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 8
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 8
- 238000011049 filling Methods 0.000 claims description 26
- 210000000582 semen Anatomy 0.000 claims description 23
- 241000736199 Paeonia Species 0.000 claims description 13
- 235000001759 Citrus maxima Nutrition 0.000 claims description 12
- 244000276331 Citrus maxima Species 0.000 claims description 12
- 241000208689 Eucommia ulmoides Species 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 10
- 238000007689 inspection Methods 0.000 claims description 10
- 238000012856 packing Methods 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 7
- 239000011591 potassium Substances 0.000 claims description 7
- 229910052700 potassium Inorganic materials 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- 239000010935 stainless steel Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 4
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 3
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 3
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 3
- 239000001138 artemisia absinthium Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 240000007087 Apium graveolens Species 0.000 claims 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims 1
- 235000010591 Appio Nutrition 0.000 claims 1
- 240000001851 Artemisia dracunculus Species 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000036039 immunity Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 5
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 3
- 238000001228 spectrum Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 18
- 239000003814 drug Substances 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 7
- 244000077995 Coix lacryma jobi Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 244000185386 Thladiantha grosvenorii Species 0.000 description 4
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 4
- 150000008130 triterpenoid saponins Chemical class 0.000 description 4
- 240000006891 Artemisia vulgaris Species 0.000 description 3
- 235000005881 Calendula officinalis Nutrition 0.000 description 3
- 240000000785 Tagetes erecta Species 0.000 description 3
- NTKNGUAZSFAKEE-UHFFFAOYSA-N capillarisin Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1OC1=CC=C(O)C=C1 NTKNGUAZSFAKEE-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- -1 triterpene compound Chemical class 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000008265 rhamnosides Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000009447 Cardiac Edema Diseases 0.000 description 1
- DPQCZNIGGNJGTD-UHFFFAOYSA-N Chloride-(??)-2-Methylpentanoic acid Natural products CCCCCCC=CCCCCCCCCCC(=O)OC(C)C(C)OC(=O)CCCCCCCC=CCCCCCC DPQCZNIGGNJGTD-UHFFFAOYSA-N 0.000 description 1
- DPQCZNIGGNJGTD-MVCBGFDASA-N Coixenolide Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)O[C@@H](C)[C@@H](C)OC(=O)CCCCCCC\C=C/CCCCCC DPQCZNIGGNJGTD-MVCBGFDASA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000014490 good eating habits Nutrition 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及食材提取物和营养素广谱抗肿瘤组合物，由以下重量份数的原料组成：赖氨酸100～200份，牛磺酸100～200份，罗汉果提取物5～15份，绿叶素铜钠5～15份，甘草酸钾5～15份，食材提取物24～64份，其余为纯净水。与现有的技术相比，本发明的有益效果是：多靶向抗肿瘤；应用范围广；安全无副作用；不影响其它抗肿瘤方法；取材方便，经济适合更多患者。控制、好转、治愈比率高于目前的任何方法，本发明的食材提取物和营养素不仅起到了改善人体机能的作用，从而达到提高人体免疫系统免疫力的目的，同时其均具有不同程度的抗肿瘤的功效，从而使本发明具有广谱、抗肿瘤的功效。
Description
技术领域
本发明涉及医药技术领域，特别涉及食材提取物和营养素广谱抗肿瘤组合物及其制备方法。
背景技术
恶性肿瘤越来越威胁到人类的健康，每天全世界大约有700万人死于恶心肿瘤，恶性肿瘤的发生与饮食结构关系密切，良好的饮食习惯和饮食结构是预防恶性肿瘤的重要措施之一，一些与预防肿瘤发生的失误因素已被研究，有的理论上已取得很大进展。
现代研究罗汉果果实中的三萜皂苷具有高甜(是蔗糖的300～400倍)、低热量和无毒副作用的特点，在食品、保健品和医药等领域具有重要的应用和商业价值。研究团队前期筛选了多种植物代谢产物，其中罗汉果中三萜皂苷对“癌中之王”胰腺癌具有显著杀伤作用，同时能延长肿瘤动物的寿命，并对肺癌、白血病、肝癌、喉癌、淋巴癌和结肠癌等多种恶性肿瘤具有杀伤作用。
此外，研究团队还发现，罗汉果中的三萜类化合物具有阻滞细胞周期、抑制肿瘤细胞转移等功能。药理研究表明，罗汉果三萜皂苷通过调控p21、cyclinD1等周期蛋白使肿瘤细胞阻滞在G0/G1期，并通过调控Bcl-2蛋白家族诱导肿瘤细胞凋亡。研究首次发现，罗汉果三萜皂苷诱导肿瘤细胞凋亡的多个信号靶点，从而为肿瘤防治药物的开发提供了药理基础。
近年来临床和基础研究指出，赤芍及其提取物对一些肿瘤有抑制作用。赤芍是赤芍的主要有效成分没食子酸酯的同系物没食子酸内酯，它是否能抑制肿瘤或及其血行转移以及如有抑制作用；万寿菊茎叶中两种黄酮类化合物4＇-甲氧基-泽兰素-3-O-β-D-葡萄糖苷(化合物Ⅰ)和山柰酚-3,7-O-α-L-双鼠李糖苷(化合物Ⅱ)的抗肿瘤活性。
薏苡仁味甘、淡，性微寒。具有利水渗湿、除痹、清热排脓、健脾止泻的功能。临床常用于心源性水肿、气喘、肺脓肿、肾炎、肾盂肾炎、脚气、小便不利、湿痹拘挛、脾虚泄泻、急性咽喉炎、扁平疣等。主要有效成分：含薏苡仁酯、薏苡仁内酯、甾醇、氨基酸、糖类、脂肪酸、维生B1、B2等。药理研究证明薏苡仁有抗肿瘤和增强免疫功能的双重作用。
茵陈为菊科艾属植物茵陈篙，具清热利湿、利胆退黄之功效，用于黄疽、肝炎、尿少色黄等，本品主要含6,7—二甲基香豆素、绿原酸、咖啡酸、茵陈色原酮、甲基茵陈色原酮等化合物，它们在体外能抑制癌细胞的增殖。
杜仲总多糖能够抑制S-180肉瘤的生长，并能够提高胸腺指数和脾指数，增加骨髓有核细胞计数及外周血白细胞计数，拮抗环磷酰胺引起的外周血白细胞和骨髓有核细胞减少。
沙苑子为豆科植物扁茎黄芪，具有温补肝肾、固精、缩尿、益肝明目的功能。药理研究表明沙苑子提取物具有改善血液流变学指标、降低血压、调节血脂、抑制血小板聚集、保护肝脏、增强免疫功能、抗炎、镇痛及调节中枢神经系。
西药对肿瘤的作用，有效率低，据网络报道治愈率只有0.5～1％，并且其副作用大，同时不具有广谱性；中药靶向性不明确，中成药很少，有效率更低，特别是以毒攻毒，副作用也较大；上述问题的产生原因是对肿瘤病理分析不准确，相差很大。对肿瘤形成的原因分析模糊，理论分歧较大，都是单靶向理论。
发明内容
本发明的目的在于提供一种克服现有技术的不足，一种抗多靶向抗肿瘤以及不影响其它抗肿瘤方法的食材提取物和营养素广谱抗肿瘤组合物。
为实现上述目的，本发明采用以下技术方案实现：
食材提取物和营养素广谱抗肿瘤组合物，由以下重量份数的原料组成：赖氨酸100～200份，牛磺酸100～200份，罗汉果提取物5～15份，绿叶素铜钠5～15份，甘草酸钾5～15份，食材提取物24～64份，其余为纯净水。
所述的食材提取物由赤芍提取物3～8份，万寿菊提取物3～8份，芹菜提取物3～8份，薏苡仁提取物3～8份，茵陈提取物3～8份，杜仲提取物3～8份，柚皮提取物3～8份，沙苑子提取物3～8份混合的混合物。
所述的组合物各组分按重量份数的优选配比为：赖氨酸150份，牛磺酸150份，罗汉果提取物10份，绿叶素铜钠10份，甘草酸钾10份，食材提取物40份，其余为纯净水。
所述的食材提取物各组分按重量份数的优选配比为：赤芍提取物5份，万寿菊提取物5份，芹菜提取物5份，薏苡仁提取物5份，茵陈提取物5份，杜仲提取物5份，柚皮提取物5份，沙苑子提取物5份。
食材提取物和营养素广谱抗肿瘤组合物的制备方法，按以下步骤完成：
(1)原料水解：分别赖氨酸、牛磺酸投入装有纯净水的不锈钢搅拌罐里进行搅拌，搅拌半小时，直到全部溶解均匀；
(2)原料混合：将水解好的原料放入混合机中，将罗汉果提取物、绿叶素铜钠、甘草酸钾放入混合机中混合，搅拌5分钟使之溶解均匀为止；
(3)原料二次混合：将赤芍提取物、万寿菊提取物、芹菜提取物、薏苡仁提取物、茵陈提取物、杜仲提取物、柚皮提取物、沙苑子提取物添加到(2)完成后得到的溶液中，搅拌5分钟使之溶解均匀为止；
(4)灌装：选取带有过滤头的灌装设备，将混合机中的物品倒入灌装桶，灌装前对灌装瓶和盖用纯净水清洗，放入消毒柜消毒检验，同时对成品进行取样检验，如有异常应该停止打包，检验标签日期是否正确、包装和标签是否一致，防止成品和标签、外包装不符合事件的发生。
按其制备方法而得到的产品成分如下表：
| 钾％ | 5.0 |
| 钠％ | 0.5 |
| 钙％ | 0.5 |
| 镁％ | ＜5.0 |
| 锌％ | ≥0.5 |
| 铜％ | ＜0.2 |
| 钼％ | ＜0.2 |
| 钒％ | ＜0.2 |
| 锰％ | ＜0.2 |
| 锡％ | ＜0.2 |
| 赖氨酸％ | 1.0 |
| 食材提取物％ | ＜1.0 |
| 水分％ | 80.0 |
与现有的技术相比，本发明的有益效果是：
多靶向抗肿瘤；应用范围广；安全无副作用；不影响其它抗肿瘤方法；取材方便，经济适合更多患者。控制、好转、治愈比率高于目前的任何方法，本发明的食材提取物和营养素不仅起到了改善人体机能的作用，从而达到提高人体免疫系统免疫力的目的，同时其均具有不同程度的抗肿瘤的功效，从而使本发明具有广谱、抗肿瘤的功效，各药自身的功效没有降低或减退，相反诸药各取长补短，相辅相成，不易使肿瘤产生抗药性和耐药性。
平时可以预先服用本发明，起到强身健体、增强免疫力的作用，抵抗细胞的癌变；一旦患有恶性肿瘤疾病，服用本发明，治疗效果也很明显，有效的抑制肿瘤的生长，而且不易使肿瘤产生抗药性和耐药性，为广谱、抗肿瘤首选。
具体实施方式
下面对本发明的具体实施方式进一步说明：
实施例一
食材提取物和营养素广谱抗肿瘤组合物，由以下重量份数的原料组成：赖氨酸100份，牛磺酸100份，罗汉果提取物5份，绿叶素铜钠5份，甘草酸钾5份，食材提取物24份，其余为纯净水。
上述的食材提取物由赤芍提取物3份，万寿菊提取物3份，芹菜提取物3份，薏苡仁提取物3份，茵陈提取物3份，杜仲提取物3份，柚皮提取物3份，沙苑子提取物3份混合的混合物。
食材提取物和营养素广谱抗肿瘤组合物的制备方法，按以下步骤完成：
(1)原料水解：分别赖氨酸、牛磺酸投入装有纯净水的不锈钢搅拌罐里进行搅拌，搅拌半小时，直到全部溶解均匀；
(2)原料混合：将水解好的原料放入混合机中，将罗汉果提取物、绿叶素铜钠、甘草酸钾放入混合机中混合，搅拌5分钟使之溶解均匀为止；
(3)原料二次混合：将赤芍提取物、万寿菊提取物、芹菜提取物、薏苡仁提取物、茵陈提取物、杜仲提取物、柚皮提取物、沙苑子提取物添加到(2)完成后得到的溶液中，搅拌5分钟使之溶解均匀为止；
(4)灌装：选取带有过滤头的灌装设备，将混合机中的物品倒入灌装桶，灌装前对灌装瓶和盖用纯净水清洗，放入消毒柜消毒检验，同时对成品进行取样检验，如有异常应该停止打包，检验标签日期是否正确、包装和标签是否一致，防止成品和标签、外包装不符合事件的发生。
按其制备方法而得到的产品成分如下表：
实施例二
食材提取物和营养素广谱抗肿瘤组合物，由以下重量份数的原料组成：牛磺酸150份，罗汉果提取物10份，绿叶素铜钠10份，甘草酸钾10份，食材提取物40份，其余为纯净水。
所述的食材提取物各组分按重量份数的优选配比为：赤芍提取物5份，万寿菊提取物5份，芹菜提取物5份，薏苡仁提取物5份，茵陈提取物5份，杜仲提取物5份，柚皮提取物5份，沙苑子提取物5份。
食材提取物和营养素广谱抗肿瘤组合物的制备方法，按以下步骤完成：
(1)原料水解：分别赖氨酸、牛磺酸投入装有纯净水的不锈钢搅拌罐里进行搅拌，搅拌半小时，直到全部溶解均匀；
(2)原料混合：将水解好的原料放入混合机中，将罗汉果提取物、绿叶素铜钠、甘草酸钾放入混合机中混合，搅拌5分钟使之溶解均匀为止；
(3)原料二次混合：将赤芍提取物、万寿菊提取物、芹菜提取物、薏苡仁提取物、茵陈提取物、杜仲提取物、柚皮提取物、沙苑子提取物添加到(2)完成后得到的溶液中，搅拌5分钟使之溶解均匀为止；
(4)灌装：选取带有过滤头的灌装设备，将混合机中的物品倒入灌装桶，灌装前对灌装瓶和盖用纯净水清洗，放入消毒柜消毒检验，同时对成品进行取样检验，如有异常应该停止打包，检验标签日期是否正确、包装和标签是否一致，防止成品和标签、外包装不符合事件的发生。
按其制备方法而得到的产品成分如下表：
| 钾％ | 5.0 |
| 钠％ | 0.5 |
| 钙％ | 0.5 |
| 镁％ | ＜5.0 |
| 锌％ | ≥0.5 |
| 铜％ | ＜0.2 |
| 钼％ | ＜0.2 |
| 钒％ | ＜0.2 |
| 锰％ | ＜0.2 |
| 锡％ | ＜0.2 |
| 赖氨酸％ | 1.0 |
| 食材提取物％ | ＜1.0 |
| 水分％ | 80.0 |
实施例三
食材提取物和营养素广谱抗肿瘤组合物，由以下重量份数的原料组成：赖氨酸200份，牛磺酸200份，罗汉果提取物15份，绿叶素铜钠15份，甘草酸钾15份，食材提取物64份，其余为纯净水。
所述的食材提取物由赤芍提取物8份，万寿菊提取物8份，芹菜提取物8份，薏苡仁提取物8份，茵陈提取物8份，杜仲提取物8份，柚皮提取物8份，沙苑子提取物8份混合的混合物。
食材提取物和营养素广谱抗肿瘤组合物的制备方法，按以下步骤完成：
(1)原料水解：分别赖氨酸、牛磺酸投入装有纯净水的不锈钢搅拌罐里进行搅拌，搅拌半小时，直到全部溶解均匀；
(2)原料混合：将水解好的原料放入混合机中，将罗汉果提取物、绿叶素铜钠、甘草酸钾放入混合机中混合，搅拌5分钟使之溶解均匀为止；
(3)原料二次混合：将赤芍提取物、万寿菊提取物、芹菜提取物、薏苡仁提取物、茵陈提取物、杜仲提取物、柚皮提取物、沙苑子提取物添加到(2)完成后得到的溶液中，搅拌5分钟使之溶解均匀为止；
(4)灌装：选取带有过滤头的灌装设备，将混合机中的物品倒入灌装桶，灌装前对灌装瓶和盖用纯净水清洗，放入消毒柜消毒检验，同时对成品进行取样检验，如有异常应该停止打包，检验标签日期是否正确、包装和标签是否一致，防止成品和标签、外包装不符合事件的发生。
按其制备方法而得到的产品成分如下表：
试验结果：
Claims (6)
1.食材提取物和营养素广谱抗肿瘤组合物，其特征在于，由以下重量份数的原料组成：赖氨酸100～200份，牛磺酸100～200份，罗汉果提取物5～15份，绿叶素铜钠5～15份，甘草酸钾5～15份，食材提取物24～64份，其余为纯净水。
2.根据权利要求1所述的食材提取物和营养素广谱抗肿瘤组合物，其特征在于，所述的食材提取物由赤芍提取物3～8份，万寿菊提取物3～8份，芹菜提取物3～8份，薏苡仁提取物3～8份，茵陈提取物3～8份，杜仲提取物3～8份，柚皮提取物3～8份，沙苑子提取物3～8份混合的混合物。
3.根据权利要求1所述的食材提取物和营养素广谱抗肿瘤组合物，其特征在于，所述的组合物各组分按重量份数的优选配比为：赖氨酸150份，牛磺酸150份，罗汉果提取物10份，绿叶素铜钠10份，甘草酸钾10份，食材提取物40份，其余为纯净水。
4.根据权利要求2所述的食材提取物和营养素广谱抗肿瘤组合物，其特征在于，所述的食材提取物各组分按重量份数的优选配比为：赤芍提取物5份，万寿菊提取物5份，芹菜提取物5份，薏苡仁提取物5份，茵陈提取物5份，杜仲提取物5份，柚皮提取物5份，沙苑子提取物5份。
5.根据权利要求1所述的食材提取物和营养素广谱抗肿瘤组合物的制备方法，其特征在于，按以下步骤完成：
(1)原料水解：分别赖氨酸、牛磺酸投入装有纯净水的不锈钢搅拌罐里进行搅拌，搅拌半小时，直到全部溶解均匀；
(2)原料混合：将水解好的原料放入混合机中，将罗汉果提取物、绿叶素铜钠、甘草酸钾放入混合机中混合，搅拌5分钟使之溶解均匀为止；
(3)原料二次混合：将赤芍提取物、万寿菊提取物、芹菜提取物、薏苡仁提取物、茵陈提取物、杜仲提取物、柚皮提取物、沙苑子提取物添加到(2)完成后得到的溶液中，搅拌5分钟使之溶解均匀为止；
(4)灌装：选取带有过滤头的灌装设备，将混合机中的物品倒入灌装桶，灌装前对灌装瓶和盖用纯净水清洗，放入消毒柜消毒检验，同时对成品进行取样检验，如有异常应该停止打包，检验标签日期是否正确、包装和标签是否一致，防止成品和标签、外包装不符合事件的发生。
6.根据权利要求5所述的食材提取物和营养素广谱抗肿瘤组合物的制备方法，其特征在于，按其制备方法而得到的产品成分如下表：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710346878.4A CN107184863A (zh) | 2017-05-16 | 2017-05-16 | 食材提取物和营养素广谱抗肿瘤组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710346878.4A CN107184863A (zh) | 2017-05-16 | 2017-05-16 | 食材提取物和营养素广谱抗肿瘤组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107184863A true CN107184863A (zh) | 2017-09-22 |
Family
ID=59873066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710346878.4A Pending CN107184863A (zh) | 2017-05-16 | 2017-05-16 | 食材提取物和营养素广谱抗肿瘤组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107184863A (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113779A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 抗乙肝制剂 |
| CN104305221A (zh) * | 2014-10-25 | 2015-01-28 | 胡安然 | 喉癌全营养配方食品 |
| CN104855973A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 喉癌非全营养配方食品 |
| CN105410929A (zh) * | 2015-11-01 | 2016-03-23 | 劲膳美生物科技股份有限公司 | 一种胃癌化疗患者食用的全营养特殊配方食品 |
| CN105435048A (zh) * | 2015-12-18 | 2016-03-30 | 赵红 | 一种治疗甲状腺肿瘤的中药 |
| CN105770420A (zh) * | 2016-03-31 | 2016-07-20 | 汤震环 | 一种具有抗癌作用的中草药剂及其制备方法 |
| CN105902668A (zh) * | 2016-06-12 | 2016-08-31 | 沈阳艾奕格生物科技有限公司 | 广谱抗病毒食材提取物与营养素的组合物及其制备方法 |
-
2017
- 2017-05-16 CN CN201710346878.4A patent/CN107184863A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113779A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 抗乙肝制剂 |
| CN104305221A (zh) * | 2014-10-25 | 2015-01-28 | 胡安然 | 喉癌全营养配方食品 |
| CN104855973A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 喉癌非全营养配方食品 |
| CN105410929A (zh) * | 2015-11-01 | 2016-03-23 | 劲膳美生物科技股份有限公司 | 一种胃癌化疗患者食用的全营养特殊配方食品 |
| CN105435048A (zh) * | 2015-12-18 | 2016-03-30 | 赵红 | 一种治疗甲状腺肿瘤的中药 |
| CN105770420A (zh) * | 2016-03-31 | 2016-07-20 | 汤震环 | 一种具有抗癌作用的中草药剂及其制备方法 |
| CN105902668A (zh) * | 2016-06-12 | 2016-08-31 | 沈阳艾奕格生物科技有限公司 | 广谱抗病毒食材提取物与营养素的组合物及其制备方法 |
Non-Patent Citations (4)
| Title |
|---|
| 刘圆等: "《中国民族药物学概论》", 30 November 2017, 四川出版集团 * |
| 南京中医药大学: "《中药大辞典》", 31 March 2006, 上海科学技术出版社 * |
| 张昌欨等: "《防癌从日常生活做起》", 31 March 2013, 金盾出版社 * |
| 王艳: "《走进大自然 草本植物》", 31 May 2013, 吉林出版集团有限责任公司 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103535596B (zh) | 一种富含膳食纤维保健粉及其制备方法 | |
| CN104127758A (zh) | 具有健脾养胃功效的中药组合物及其制备方法和应用 | |
| CN103893565A (zh) | 一种清咽止咳茶及其制作方法 | |
| CN104138526B (zh) | 一种乌药铁皮人参颗粒剂 | |
| CN106376927A (zh) | 一种对化学性肝损伤具有辅助保护作用的保健品 | |
| CN103892139A (zh) | 饲料用中草药添加剂 | |
| CN108713746A (zh) | 一种药食同源组合物及其制备方法和应用 | |
| CN105076728B (zh) | 富硒中草药饲料添加剂及其制备方法 | |
| CN110604773A (zh) | 调节脂代谢紊乱的组合物及其制备方法和用途 | |
| CN110367522A (zh) | 一种用于增强免疫力的药膳组合物及其制备方法 | |
| CN1173726C (zh) | 一种治疗恶性肿瘤病的药物及其制备方法 | |
| CN107184863A (zh) | 食材提取物和营养素广谱抗肿瘤组合物及其制备方法 | |
| CN104489716A (zh) | 预防与治疗人体心血管疾病的保健制剂及其制作方法 | |
| CN105981934A (zh) | 富硒肉兔饲料及其饲养方法 | |
| CN104256376A (zh) | 一种辅助抑制肿瘤的营养代餐粉 | |
| CN103211868B (zh) | 一种预防骨质疏松的组合物 | |
| CN102090626A (zh) | 一种糖尿病患者的食品配料及制作方法 | |
| CN104694310A (zh) | 一种具有降脂功效的葡萄酒 | |
| CN105533737A (zh) | 一种含艾叶提取物的黑蒜口服液及其制备方法和用途 | |
| CN104664205A (zh) | 一种红虎玛免疫促进颗粒及其制作方法 | |
| CN105349394B (zh) | 一种接骨木食醋及其制备方法 | |
| KR101636612B1 (ko) | 복분자와 황기 혼합추출물을 포함하는 골다공증 예방 및 치료용 조성물 | |
| CN101912449B (zh) | 一种治疗肝炎的药物及其制备工艺 | |
| CN109805311A (zh) | 抗亚硝胺防乳腺癌的保健品 | |
| CN108450761A (zh) | 一种补气养血增强免疫的营养粉及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170922 |
|
| WD01 | Invention patent application deemed withdrawn after publication |